249 related articles for article (PubMed ID: 19854285)
21. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
22. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
23. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
24. Mucolytics for bronchiectasis.
Wilkinson M; Sugumar K; Milan SJ; Hart A; Crockett A; Crossingham I
Cochrane Database Syst Rev; 2014 May; 2014(5):CD001289. PubMed ID: 24789119
[TBL] [Abstract][Full Text] [Related]
25. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Black PN
Cochrane Database Syst Rev; 2010 Feb; (2):CD001287. PubMed ID: 20166060
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
27. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
28. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
[TBL] [Abstract][Full Text] [Related]
29. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
Dal Negro RW; Visconti M; Micheletto C; Tognella S
Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of a complementary antiinflammatory treatment with erespal in chronic obstructive and nonobstructive bronchitis].
Volkova LI; Budkova AA; Filonova NN; Khristoliubova EI; Kutuzova EB; Koroleva NV; Radzivil TT; Aminova ZR; Chuchalin AG
Ter Arkh; 2004; 76(8):51-6. PubMed ID: 15471398
[TBL] [Abstract][Full Text] [Related]
31. Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.
Monz BU; Sachs P; McDonald J; Crawford B; Nivens MC; Tetzlaff K
Respir Med; 2010 Apr; 104(4):534-41. PubMed ID: 19917525
[TBL] [Abstract][Full Text] [Related]
32. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
33. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ; Black PN
Cochrane Database Syst Rev; 2006 Jul; (3):CD001287. PubMed ID: 16855965
[TBL] [Abstract][Full Text] [Related]
34. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
36. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ; Black PN
Cochrane Database Syst Rev; 2003; (2):CD001287. PubMed ID: 12804402
[TBL] [Abstract][Full Text] [Related]
37. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
39. The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD).
Davies L; Calverley PM
Br Med Bull; 2010; 93():217-27. PubMed ID: 20031934
[TBL] [Abstract][Full Text] [Related]
40. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
